t
Cambridge Cognition Holdings plc issued 229,984 new ordinary shares on 26 July 2024 at an issue price of 132.97 pence per share to certain former shareholders of eClinicalHealth Limited. This issuance, representing approximately £0.3m, completed the contingent consideration for the Clinpal acquisition, with no further consideration due. Application has been made for these shares to be admitted to AIM on or around 31 July 2024, resulting in the Company's total voting rights comprising 41,940,413 Ordinary Shares.
| Date | 26 Jul 2024 |
| Time | 07:00:05 |
| Category | Capital structure |
| ID | 9167X |
26 July 2024
Cambridge Cognition Holdings plc
("Cambridge Cognition", the "Company" or the "Group")
Issue of Equity and Total Voting Rights
Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces that further to the announcement on 12 October 2022 regarding the acquisition of eClinicalHealth Limited ("Clinpal"), the Company has today issued 229,984 new ordinary shares of £0.01 each in the share capital of the Company ("New Ordinary Shares") at an issue price of 132.97 pence per New Ordinary Share to certain shareholders of Clinpal, representing approximately £0.3m of the contingent consideration. No further consideration is due to former shareholders of Clinpal.
Admission and Total Voting Rights
Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that such Admission will take place on or around 8:00 a.m. on or around 31 July 2024.
In accordance with the provision of the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority, the Company confirms that, following the issue of the New Ordinary Shares, its issued ordinary share capital will comprise 41,940,413 Ordinary Shares. There are no shares held in treasury therefore the total number of voting rights in the Company is 41,940,413. This figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in Cambridge Cognition under the FCA's Disclosure and Transparency Rules.
Enquiries:
|
|
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
For further information visit: https://cambridgecognition.com/